Down syndrome regression disorder responsive to immunoglobulin modulation therapy

Down syndrome (DS), caused by trisomy 21 in ~95% of cases, carries three copies of the chromosome 21 interferon receptor cluster (IFNAR1, IFNAR2, IFNGR2, and IL10RB), leading to a constitutive, mild interferonopathy across types I, II, and III signalling. Down syndrome regression disorder (DSRD) is a devastating neuro-regression occurring between 10 and 30 years. A sub-group shares immunological and neuroimaging features with the monogenic type I interferonopathies, though the mechanism differs: trisomy 21 confers receptor-level over-responsiveness rather than ligand excess. DSRD remains a diagnosis of exclusion but commonly arises on a background of pre-existing neurodevelopmental or neuropsychiatric comorbidity, so identifying a comorbidity does not itself exclude it. Both adolescents described here presented with severe neuropsychiatric regression, symmetric basal ganglia mineralization, and an isolated elevation of the interferon-stimulated gene IFI27. No commissioning pathway for DSRD immune-directed therapy exists in the United Kingdom (UK). Approximately 21 months after onset, intravenous immunoglobulin (IVIG) was commenced in both, for the first time in the UK: 2 g/kg loading then eight monthly doses of 1 g/kg. Nine doses produced partial but clinically meaningful multidomain improvement without serious adverse events. Serial IFI27 fell in both but remained above the reference interval throughout; it did not track clinical response. These descriptive observations require confirmation in controlled studies. Inability to access workup and treatment is a health inequity; early recognition and a multidisciplinary approach spanning neurology, psychiatry, and immunology are needed.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.2022809
Primary Topic
Down syndrome and intellectual disability research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Down syndrome regression disorder responsive to immunoglobulin modulation therapy

Olivier Broucke, Kimberly Gilmour, Konstantinos Vazouras, Iek Leng Cheng et al.
Frontiers in Immunology
Down syndrome and intellectual disability research
article

Down syndrome regression disorder responsive to immunoglobulin modulation therapy

Olivier Broucke, Kimberly Gilmour, Konstantinos Vazouras, Iek Leng Cheng, E. S. Rachamim, Ashley Liew, Shahid H. Zaman, Paramala Santosh, Kshitij Mankad, Marios Kaliakatsos, Eleanor J. Molloy, Maaike Kusters, Abinaya Seenivasan, Reem Elfeky, Jessica Laxaman, M Davis, Ellie Simmonds, Arlene Barcenilla
article en

Abstract

Down syndrome (DS), caused by trisomy 21 in ~95% of cases, carries three copies of the chromosome 21 interferon receptor cluster (IFNAR1, IFNAR2, IFNGR2, and IL10RB), leading to a constitutive, mild interferonopathy across types I, II, and III signalling. Down syndrome regression disorder (DSRD) is a devastating neuro-regression occurring between 10 and 30 years. A sub-group shares immunological and neuroimaging features with the monogenic type I interferonopathies, though the mechanism differs: trisomy 21 confers receptor-level over-responsiveness rather than ligand excess. DSRD remains a diagnosis of exclusion but commonly arises on a background of pre-existing neurodevelopmental or neuropsychiatric comorbidity, so identifying a comorbidity does not itself exclude it. Both adolescents described here presented with severe neuropsychiatric regression, symmetric basal ganglia mineralization, and an isolated elevation of the interferon-stimulated gene IFI27. No commissioning pathway for DSRD immune-directed therapy exists in the United Kingdom (UK). Approximately 21 months after onset, intravenous immunoglobulin (IVIG) was commenced in both, for the first time in the UK: 2 g/kg loading then eight monthly doses of 1 g/kg. Nine doses produced partial but clinically meaningful multidomain improvement without serious adverse events. Serial IFI27 fell in both but remained above the reference interval throughout; it did not track clinical response. These descriptive observations require confirmation in controlled studies. Inability to access workup and treatment is a health inequity; early recognition and a multidisciplinary approach spanning neurology, psychiatry, and immunology are needed.

Frontiers in ImmunologyVol. 17
Royal Free London NHS Foundation Trust (GB), King's College London (GB), South London and Maudsley NHS Foundation Trust (GB), Trinity College Dublin (IE), University of Cambridge (GB), Great Ormond Street Hospital (GB), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), Hertfordshire Community NHS Trust (GB), Cambridgeshire and Peterborough NHS Foundation Trust (GB), Evelina London Children's Healthcare (GB), Royal Manchester Children's Hospital (GB), Institute of Infection and Immunity (CA), University College London (GB)
Down syndrome and intellectual disability research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon